Yes I here you nice to see a big green msb on my portfolio.
I guess my concern is when the dust settles the reality that we still have no approval and the FDA seems to have set such a high bar for MSB that there is no guarantees on any of their trials. That is why I feel disappointed that significant news was slipped in.
Really hope the Covid-19 trial is successful the FDA emergency use standards are more flexible which is positive but if they make it run to 300 patients it could be that vaccines are being distributed which purely from a stock point of view would give us less of a boost.
Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-301
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.005(0.51%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 98.5¢ | 98.5¢ | 96.0¢ | $2.168M | 2.226M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16000 | 96.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.0¢ | 86854 | 7 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |